Growth Hormone, IGF-1, and Aging: What's Evidence-Based and What's Hype
Growth Hormone, IGF-1, and Aging: What’s Evidence-Based and What’s Hype
Growth hormone occupies a unique position in longevity medicine. It is among the most aggressively marketed interventions, often presented as a near-mythical anti-aging tool. It is also one of the most clinically nuanced. The evidence supports specific use in specific conditions and does not support the broad use that has made it commercially popular.
For patients evaluating an offer of growth hormone or one of its secretagogues — sermorelin, CJC-1295, ipamorelin, tesamorelin — the question is not whether these molecules exist or have biological effect. They do, and they do. The question is whether the evidence supports the proposed use in their particular circumstance, and whether the monitoring is in place to identify benefit versus harm.
This is a growth hormone evaluation that takes the clinical literature seriously rather than the marketing.
What Growth Hormone Does
Human growth hormone (hGH, somatotropin) is a peptide hormone secreted by the anterior pituitary in pulsatile fashion, predominantly during deep sleep. Its secretion is highest during adolescence and declines progressively through adulthood, with most adults experiencing roughly half the peak adolescent levels by age sixty.
The downstream effector of growth hormone in most tissues is insulin-like growth factor 1 (IGF-1), produced primarily by the liver in response to GH stimulation. IGF-1 has a much longer half-life than GH itself and is the standard surrogate marker for integrated GH activity.
The physiological roles of GH and IGF-1 include muscle protein synthesis, lipolysis (particularly visceral fat), bone density maintenance, connective tissue health, immune function, and metabolic regulation. The age-related decline in these processes correlates with declining GH/IGF-1 in many individuals, which has driven the interest in supplementation.
The relationship is, however, more complicated than a simple deficiency-replacement model. Higher IGF-1 levels are associated with increased muscle mass and improved body composition, but they are also associated, in some long-term studies and animal models, with accelerated aging and increased cancer risk. The lifespan and cancer literature in low-IGF-1 populations (those with Laron syndrome, for instance) suggest that lower lifelong IGF-1 may be protective rather than detrimental.
This is the clinical paradox at the centre of GH therapy: the same molecule that supports tissue repair and body composition may, in excess, accelerate the aging process it is being used to slow.
Where the Evidence Is Solid
Adult growth hormone deficiency. Confirmed by stimulation testing (insulin tolerance test, glucagon stimulation, or arginine-GHRH testing), adult GH deficiency is a defined clinical syndrome. Symptoms include central adiposity, reduced lean mass, low energy, impaired cardiovascular fitness, and reduced quality of life. Replacement therapy with recombinant hGH in this population produces measurable and clinically meaningful improvement in body composition, lipid profile, and quality of life. The evidence base is robust, the indication is approved, and the monitoring standards are established.
Specific paediatric and rare-disease indications. Turner syndrome, Prader-Willi syndrome, idiopathic short stature in children, chronic kidney disease in children, and certain other defined conditions have approved GH indications with clear evidence.
Tesamorelin in HIV-associated lipodystrophy. Tesamorelin is a GHRH analogue that stimulates pituitary GH release. It has FDA and Health Canada approval for the reduction of visceral adipose tissue in HIV-associated lipodystrophy and has the strongest evidence base of any GH secretagogue. The benefit is specific to this population and indication.
In each of these cases, the evidence-based use is for a defined clinical syndrome with established diagnostic criteria, and the treatment improves the syndrome’s specific manifestations.
Where the Evidence Is Thin
The use of growth hormone or GH secretagogues in healthy adults for general longevity, body composition improvement, or anti-aging purposes is the area where claims most outpace evidence.
Recombinant hGH in healthy older adults. The single most cited study — the 1990 Rudman trial in the New England Journal of Medicine — demonstrated improvements in body composition in twelve men over six months. Subsequent larger and longer studies have confirmed body composition changes but raised significant concerns about side effects: insulin resistance, fluid retention, joint pain, carpal tunnel syndrome, and theoretical long-term risks. Meta-analyses have consistently concluded that the risk-benefit ratio in healthy older adults does not support routine use.
Sermorelin, CJC-1295, ipamorelin, and combinations. These are peptides that stimulate the pituitary to release endogenous GH. They are widely offered in longevity clinics with claims about body composition, sleep quality, recovery, and skin. The clinical evidence in healthy adults is sparse. Most published data comes from short-duration studies in specific populations, with limited follow-up. The body composition effects, where measurable, tend to be modest. The sleep and recovery claims are largely supported by patient report rather than controlled trial data.
This does not mean these peptides are useless. They have a plausible mechanism, they are biologically active, and some patients report meaningful benefit. It does mean that they should not be presented as evidence-based interventions on a par with GLP-1 receptor agonists or established hormone replacement therapy. The evidence is at a different level of maturity, and a physician prescribing them should be honest about that.
Long-term safety. The chronic use of GH secretagogues in healthy adults has not been studied for the durations that would be required to detect cancer, cardiovascular, or accelerated-aging endpoints. The absence of evidence of harm in short-term studies is not evidence of long-term safety.
What Responsible Use Looks Like
When GH or its secretagogues are clinically appropriate — defined deficiency, specific indication, or careful informed-consent off-label use — responsible monitoring includes:
Baseline. IGF-1 level (the surrogate for integrated GH activity), fasting glucose and insulin, HbA1c, lipid panel with ApoB, full thyroid panel, body composition assessment when available, and documentation of the specific clinical question being addressed.
Stimulation testing in suspected deficiency. A single low IGF-1 is not diagnostic of GH deficiency. The diagnosis requires stimulation testing in a controlled setting. Many clinics that prescribe GH or secretagogues do not perform this step, which means they are treating a presumption rather than a diagnosis.
Ongoing monitoring. IGF-1 levels every three to six months, with the target range typically the upper-middle of the normal range for the patient’s age, not above. Glycemic monitoring because GH antagonizes insulin and can produce or worsen insulin resistance. Body composition tracking. Symptom assessment for joint pain, fluid retention, and carpal tunnel symptoms.
Cancer surveillance. Age-appropriate cancer screening becomes more important, not less. Patients with elevated IGF-1 at the upper end of the normal range may have somewhat higher cancer risk at population level; this does not contraindicate therapy in a properly selected patient but does inform the surveillance strategy.
Dose calibration. GH and secretagogues should be titrated based on IGF-1 response, not based on subjective benefit alone. The physiological dose target — IGF-1 in the upper-middle of the age-adjusted normal range — is far below the supraphysiological doses sometimes used in performance contexts. Higher is not better.
Where GH Fits in the Larger Picture
The interventions with the strongest evidence for body composition, longevity, and healthspan extension remain unchanged: resistance training, cardiovascular conditioning, adequate protein intake, sleep restoration, metabolic health correction, and where appropriate, hormonal optimization of the major axes (testosterone, estrogen, progesterone, thyroid).
A patient who is training, eating, sleeping, and metabolically optimized and still has body composition or recovery deficits has a different conversation available. A patient whose foundations are not in place, who is offered GH or peptides as a substitute for the work, is being sold a shortcut that the evidence does not support.
The Vis Viva framework is structurally suited to this evaluation. Pulsus tracks IGF-1 and the metabolic markers that determine appropriateness. Sensus tracks the symptomatic benefit. Virtus tracks the functional outcome — VO2 max, strength, body composition — that integrates whether the intervention produced clinical benefit beyond moving a number.
The number alone is not the goal. The body’s actual capacity is.
What to Ask Your Physician
If you are evaluating a growth hormone or peptide offer, several questions move the conversation forward.
What is my baseline IGF-1, and what is the target range you would aim for? Has stimulation testing been considered or performed? What is the specific evidence for this molecule at this dose in my situation? What are the known and theoretical risks, and how will they be monitored? How does this fit alongside resistance training, cardiovascular fitness, sleep, and nutrition — which the evidence supports more strongly?
A physician who can answer these questions specifically is practicing medicine. A physician who relies on mechanism and patient testimonial is selling enthusiasm.
Continue Reading
If you found this useful, these related articles may deepen your understanding:
- What Peptide Therapy Is and Isn’t: A Physician’s Honest Take
- VO2 Max: The Single Best Predictor of How Long You’ll Live
- Supplements That Actually Matter vs. Expensive Placebos
Dr. Handsun Xiao is a McGill trained physician (MD, CCFP) practicing functional medicine and bioidentical hormone therapy in Toronto, with virtual consultations available to patients across Ontario. He holds advanced BHRT certification through WorldLink Medical and IFM AFMCP training. Manus Solis offers physician led BHRT consultations with custom compounding through a dedicated Ontario compounding pharmacy partner Trutina. To learn more or book a virtual consultation, visit manussolis.ca.
Continue Reading